Literature DB >> 19936974

mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis.

Quan Zhou1, Zhansheng Deng, Yong Zhu, Haitao Long, Shaoxian Zhang, Jiali Zhao.   

Abstract

The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells' survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients' prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19936974     DOI: 10.1007/s12032-009-9365-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

Review 1.  PI3K/Akt/mTOR pathway as a target for cancer therapy.

Authors:  Daniel Morgensztern; Howard L McLeod
Journal:  Anticancer Drugs       Date:  2005-09       Impact factor: 2.248

2.  Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer.

Authors:  F J Couch; X Y Wang; G J Wu; J Qian; R B Jenkins; C D James
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

3.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Authors:  M Bärlund; F Forozan; J Kononen; L Bubendorf; Y Chen; M L Bittner; J Torhorst; P Haas; C Bucher; G Sauter; O P Kallioniemi; A Kallioniemi
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

Review 4.  Primary bone osteosarcoma in the pediatric age: state of the art.

Authors:  Alessandra Longhi; Costantino Errani; Massimiliano De Paolis; Mario Mercuri; Gaetano Bacci
Journal:  Cancer Treat Rev       Date:  2006-07-24       Impact factor: 12.111

5.  Prognostic relevance of increased angiogenesis in osteosarcoma.

Authors:  Michael Kreuter; Ralf Bieker; Stefan S Bielack; Tanja Auras; Horst Buerger; Georg Gosheger; Heribert Jurgens; Wolfgang E Berdel; Rolf M Mesters
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

Review 6.  VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma.

Authors:  Quan Zhou; Yong Zhu; Zhansheng Deng; Haitao Long; Shaoxian Zhang; Xingli Chen
Journal:  Surg Oncol       Date:  2011-03       Impact factor: 3.279

7.  A system for the surgical staging of musculoskeletal sarcoma.

Authors:  W F Enneking; S S Spanier; M A Goodman
Journal:  Clin Orthop Relat Res       Date:  1980 Nov-Dec       Impact factor: 4.176

Review 8.  Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Authors:  Courtney A Granville; Regan M Memmott; Joell J Gills; Phillip A Dennis
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

9.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Authors:  Pradip K Majumder; Phillip G Febbo; Rachel Bikoff; Raanan Berger; Qi Xue; Louis M McMahon; Judith Manola; James Brugarolas; Timothy J McDonnell; Todd R Golub; Massimo Loda; Heidi A Lane; William R Sellers
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

10.  Survivin as a prognostic factor for osteosarcoma patients.

Authors:  Eiji Osaka; Takashi Suzuki; Shunzo Osaka; Yukihiro Yoshida; Hideyuki Sugita; Satoru Asami; Keiichi Tabata; Akihiro Hemmi; Masahiko Sugitani; Norimichi Nemoto; Junnosuke Ryu
Journal:  Acta Histochem Cytochem       Date:  2006-05-26       Impact factor: 1.938

View more
  28 in total

1.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

Authors:  Gatien Moriceau; Benjamin Ory; Laura Mitrofan; Chiara Riganti; Frédéric Blanchard; Régis Brion; Céline Charrier; Séverine Battaglia; Paul Pilet; Marc G Denis; Leonard D Shultz; Jukka Mönkkönen; Françoise Rédini; Dominique Heymann
Journal:  Cancer Res       Date:  2010-10-22       Impact factor: 12.701

3.  Targeting osteosarcoma.

Authors:  Darien E Reed; Kevan M Shokat
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 4.  The pharmacogenomics of osteosarcoma.

Authors:  M Serra; C M Hattinger
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 5.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

6.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Authors:  Jennifer A Perry; Adam Kiezun; Peter Tonzi; Eliezer M Van Allen; Scott L Carter; Sylvan C Baca; Glenn S Cowley; Ami S Bhatt; Esther Rheinbay; Chandra Sekhar Pedamallu; Elena Helman; Amaro Taylor-Weiner; Aaron McKenna; David S DeLuca; Michael S Lawrence; Lauren Ambrogio; Carrie Sougnez; Andrey Sivachenko; Loren D Walensky; Nikhil Wagle; Jaume Mora; Carmen de Torres; Cinzia Lavarino; Simone Dos Santos Aguiar; Jose Andres Yunes; Silvia Regina Brandalise; Gabriela Elisa Mercado-Celis; Jorge Melendez-Zajgla; Rocío Cárdenas-Cardós; Liliana Velasco-Hidalgo; Charles W M Roberts; Levi A Garraway; Carlos Rodriguez-Galindo; Stacey B Gabriel; Eric S Lander; Todd R Golub; Stuart H Orkin; Gad Getz; Katherine A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

7.  Treatment of Bone Tumors.

Authors:  Rajiv Rajani; C Parker Gibbs
Journal:  Surg Pathol Clin       Date:  2012-03

Review 8.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015

9.  Lysophosphatidic acid acyltransferase β (LPAATβ) promotes the tumor growth of human osteosarcoma.

Authors:  Farbod Rastegar; Jian-Li Gao; Deana Shenaq; Qing Luo; Qiong Shi; Stephanie H Kim; Wei Jiang; Eric R Wagner; Enyi Huang; Yanhong Gao; Jikun Shen; Ke Yang; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Jinyong Luo; Xiaoji Luo; Yang Bi; Xing Liu; Mi Li; Ning Hu; Linyuan Wang; Gaurav Luther; Hue H Luu; Rex C Haydon; Tong-Chuan He
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

10.  Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells.

Authors:  Xiaodong Mu; Christian Isaac; Trevor Schott; Johnny Huard; Kurt Weiss
Journal:  Sarcoma       Date:  2013-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.